Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...
The distinction between the mind and the brain has been a longstanding philosophical and scientific debate that continues to shape our understanding of human consciousness. While the brain is a tangible, biological organ composed of neurons and synaptic connections, the mind represents the abstract domain of thoughts, emotions, perception, and self-awareness. This paper explores the conceptual...
Hypnosis has traditionally been conceptualized as a clinical technique for reducing physiological symptoms (e.g., pain, nausea) and psychological symptoms (e.g., anxiety, intrusive thoughts), yet emerging neuroscientific evidence suggests it operates through the fundamental mechanisms of emotional regulation and self-integration. This integrative review synthesizes research on clinical hypnosis...
Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of alternative methods, including exercise and psychedelics. While interventions using either exercise or psychedelics have demonstrated largely positive results in isolation, their synergistic potential has yet to be explored. As such,...
Eating disorders (EDs) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psilocybin treatment (PT) demonstrates therapeutic potential to enhance CBT-ED by exerting several neurobiological, psychological, and experiential effects (e.g., antidepressant, neuroplasticity, emotional openness) that are hypothesized to increase...
IntechOpen eBooksMarch 5, 2026A. M. Roy, Sushil Prasad Mahato, Deepti Padmanabha Bhat et al.
Cognitive enhancement is increasingly pursued through complementary mind–body therapies that target fundamental brain–body mechanisms. This chapter synthesizes evidence for core modalities such as meditation and yoga, and additional approaches including Tai Chi/Qigong, breathwork, and music-based interventions. Across healthy and clinical populations, these therapies produce modest yet reliable...
HealthcareMarch 3, 2026Paul Lie, Titus Lie, Madeleine Nguyen et al.1 citation
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for acute suicidality. Long-term suicide rates continue to increase in the United States and in many other countries, creating a pressing public health challenge with a variety of treatment considerations. Existing standard-of-care SSRI therapeutics have...
Introdução: A depressão resistente ao tratamento (DRT) exige novas abordagens que superem a limitação dos antidepressivos convencionais. O renascimento dos psicodélicos, especialmente da psilocibina, surge como uma alternativa promissora baseada na modulação da neuroplasticidade. Metodologia: Revisão integrativa da literatura realizada em bases de dados científicas (PubMed, SciELO, LILACS), com...
Major depressive disorder (MDD) is increasingly viewed as a disorder of impaired neural plasticity, yet the mechanisms underlying diverse antidepressant classes - glutamatergic (e.g., ketamine), monoaminergic (e.g., selective serotonin reuptake inhibitors (SSRIs)), and GABAergic (e.g., neurosteroids) - remain incompletely integrated. The objective of this study was to extend a...
If consciousness can operate under quantum principles, then the boundaries between life, death, and cognition are far more permeable than current science allows. In the first large-scale, randomized, double-blind, multicenter trial to test this possibility, conducted across 13 hospitals in the UK and Spain, we investigated whether the human mind can access information during clinical death—but...